Investor Home

Corporate Profile

Apricus is committed to developing novel therapies in areas of high unmet needs. We have disciplined leadership focused on execution and are driving near-term shareholder value through regulatory approval, commercialization and partnering initiatives.

Recent Newsmore >
DateTitle
09/11/17Apricus Biosciences Announces $3.7 Million Private Placement Priced At-The-Market
SAN DIEGO, Sept. 11, 2017 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that it has entered into definitive agreements to sell securities to certain accredited investors in a private placement priced at-the-market, for aggregate gross proceeds of approximately $3.7 million. The closing of the private placement is expected to occur on or about September 13, 2017, subject to sat... 
09/05/17Apricus Biosciences to Present at the Rodman & Renshaw 19th Annual Global Investment Conference
SAN DIEGO, Sept. 05, 2017 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that Richard W. Pascoe, Chief Executive Officer, will present at the Rodman & Renshaw 19th Annual Global Investment Conference on Tuesday, September 12, 2017, at 11:40 a.m. Eastern Time.  The conference will be held at The Lotte New York Palace Hotel in New York, NY.  Mr. Pascoe will provide an update ... 
08/31/17Apricus Biosciences Announces FDA Acknowledgement of Vitaros™ Class 2 NDA Resubmission
PDUFA Goal Date of February 17, 2018 SAN DIEGO, Aug. 31, 2017 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that the U.S. Food and Drug Administration (“FDA”) has acknowledged receipt of its recently resubmitted New Drug Application (“NDA”) for Vitaros™ (alprostadil, DDAIP.HCl) and considers it a complete, class 2 response to Apricus’ 2008 action letter.  The PDUFA (Prescript... 
Event Calendarmore >
September 2017?
Calendar Help
This calendar contains six months of past and future company related information, which may include press releases, SEC filings, calendar events and more. Dates containing information are indicated by a colored background. You may hover your mouse over a date that contains an event to reveal the event or events taking place on that day including a link to additional information. This calendar requires JavaScript to be installed and activated on your browser.
Calendar Icon Legend:
Analyst Meeting
Conference
Conference Presentation
Corporate Conference Call
Custom Events
Earnings Conference Call
Earnings Release
Financial Reports
Mergers & Acquisition Announcement
Guidance Announcement
Other Corporate
Sales Call/Presentation
Sales Release
Shareholders Meeting
News Release
SEC Filings
Presentations
52 Week High
Today
SMTWTFS
-5-4-3-2-11
09/01/17
4
Formats:  HTML Adobe PDF Word
2
34567
09/07/17
4
Formats:  HTML Adobe PDF Word
4
Formats:  HTML Adobe PDF Word
4
Formats:  HTML Adobe PDF Word
89
10111213141516
17181920
09/20/17
SC 13G
Formats:  Excel HTML Adobe PDF Word
212223
2425
09/25/17
S-3
Formats:  Excel HTML Adobe PDF Word
RW
Formats:  HTML Adobe PDF Word
2627282930
Receive E-mail AlertsE-mail Alert Icon
Sign up to receive e-mail alerts whenever Apricus Biosciences, Inc. posts new information to the site. Just enter your e-mail address and click Submit.